WASHINGTON D.C., November 6 /PRNewswire-FirstCall/ -- In a business
update, Danish-based biopharmaceutical company Bavarian Nordic, reported a
number of developments in its vaccine project pipeline.
IMVAMUNE(R) next-generation smallpox vaccine
Clinical development of IMVAMUNE(R) as a safe smallpox vaccine is
proceeding as planned. Phase III studies with IMVAMUNE(R) in healthy
subjects are expected to be initiated in 2008.